Aardvark Therapeutics, Inc. Common Stock

AARDNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
3.68 USD
↘ 0.26 (6.60%)AT CLOSE (11:59 AM EDT)
3.93
↗ 0.25 (6.79%)
POST MARKET (AS OF 06:26 PM EDT)
Post Market
AS OF 06:26 PM EDT
3.93
↗ 0.25 (6.79%)
🔴Market: CLOSED
Open?$3.91
High?$3.98
Low?$3.66
Prev. Close?$3.94
Volume?139.9K
Avg. Volume?164.7K
VWAP?$3.78
Rel. Volume?0.85x
Bid / Ask
Bid?$3.09 × 100
Ask?$5.07 × 100
Spread?$1.98
Midpoint?$4.08
Valuation & Ratios
Market Cap?80.3M
Shares Out?21.8M
Float?11.0M
Float %?50.6%
P/E Ratio?N/A
P/B Ratio?0.92
EPS?-$3.20
Dividend?0.00%
Ex-Dividend?N/A

Aardvark Therapeutics, Inc. Common Stock (AARD) trades at $3.68 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Themes
Biotech - Drug Development›Metabolic & CardiometabolicBiotech - Drug Development›Rare Disease Therapeutics
Employees
40
Market Cap
80.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aardvarktherapeutics.com
Listed
2025-02-13
Address
4370 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
Phone: (858) 225-7696
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
7
Momentum?
23
Short Sent.?
70
Piotroski F-Score?0/9Weak
Altman Z-Score?0.70Distress
Confidence?41%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.20%Elevated
Short Interest?1.0M
Days to Cover?5.5
Free Float11.0M
Avg Daily Volume183.7K
Settlement Date2026-05-15
Financial Health
Current Ratio?8.06Strong
Quick Ratio?8.06Strong
Cash Ratio?5.38Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.92CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-80.3%WEAK▾
ROA?
S&P
3
-70.9%WEAK▾
Cash Flow & Enterprise
FCF?$-61748000
Enterprise Value?$17.8M
Fundamentals ratios updated end of day
MarketsMoversWatchlist